Jonathan Adam Feldschuh, the Chief Scientific Officer of Daxor Corp (NYSE:NASDAQ:DXR), recently acquired 32,000 shares of the company's common stock. The transaction, dated December 6, 2024, was a grant with no monetary exchange, as indicated by the transaction price of $0 per share. The company, trading at $8.76, has shown resilience with a 10% return over the past year, despite its tendency to move counter to broader market trends with a beta of -0.51. Following this acquisition, Feldschuh's total direct ownership in the company stands at 35,908 shares. This transaction reflects a vesting of shares granted to Feldschuh, as noted in the filing. While Daxor maintains profitability with a 100% gross margin, InvestingPro analysis reveals the company operates with moderate debt levels and faces some liquidity challenges. Subscribers can access 6 additional key insights about Daxor's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.